Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

The Outcome of the Pfizer/Allergan Marriage. See Also: More News for Incyte

April 6, 2016 0

Pfizer (PF) terminated its acquisition agreement with Allergan Plc (AGN) The new set of rules released by …

Expected and Unexpected Reasons for Pfizer and Intercept Stocks’ Rallies

April 5, 2016 0

PFIZER Pfizer (PF) announced that its oral drug tofacitinib in doses of 5 mg and 10 mg …

Prohost Letter #394 Part 2

April 4, 2016 0

Prohost Letter #394 Part 2 PART 2 - Part 1 of the Prohost letter issue #394 posted …

Gilead’s Well Chosen New Acquisition Is Not the Last, It Is Just the Beginning

April 4, 2016 0

Many in Wall Street have been anxious, sitting on fire while waiting to learn, which biotech …

Prohost Letter #394 Part 1

April 1, 2016 0

Prohost Letter #394 Part 1 Gilead - Some people sold Gilead’s (GILD) stock on Wednesday, March 23 …

News from Incyte and Gossip About Medivation

March 31, 2016 0

Incyte (INCY) and Eli Lilly (LLY): The New England Journal of Medicine published detailed results of RA-BEACON — a pivotal …

The FDA Says Yes to Acadia Drug Nuplazid and More

March 30, 2016 0

The U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) voted 12 to 2 …

Alder Biopharmaceutical Migraine Headache Drug Passes the Test. Our Voting Regarding Acadia Drug Nuplazid Approval

March 28, 2016 0

Alder Reports Phase 2b Trial of ALD403 Meets Primary and Secondary Endpoints Demonstrating Migraine Prevention in …

Portola Is Still a Favorite

March 24, 2016 0

It is an ingenuous decision made by investors who rushed to consider betrixaban Phase 3 APEX study a …

Amgen: Positive Data from Osteoporosis Trial. Aerie Pharmaceuticals: More Data on Glaucoma Drug Safety.

March 22, 2016 0

Amgen (AMGN) and UCB (Euronext Brussels: UCB) announced positive results from the BRIDGE pivotal Phase 3 placebo-controlled …

Vitae Pharmaceuticals: Opening a New Door Towards the Management of Psoriasis. The Drug Could Be Great for Many Other Autoimmune Diseases.

March 17, 2016 0

Published articles in peer review journals cited that pharmacologic inhibition of RORγt regulates Th17 signature gene expression …

Immunokinases Attract Roche to Blueprint Medicine. Spectrum Granted FDA Approval.

March 16, 2016 0

Immunotherapy for Cancer Blueprint Medicines Blueprint Medicines (BPMC) entered into a worldwide collaboration and exclusive license agreement …

Celator: Improving on AML Standard of Care Treatment. The Stock Rallied.

March 15, 2016 0

First therapy to demonstrate statistically significant improvement in overall survival and induction response rate in a …

GW Pharmaceuticals: A Cannabinoid Product Succeeds in Treating a Resistant Epilepsy. Stock Price Doubled.

March 14, 2016 0

London, UK, 14 March 2016: GW Pharmaceuticals (GWPH), is a biopharmaceutical company focused on discovering, developing and …

Xoma: The Considered Dead is Alive and Kicking. Gilead is Way Undervalued

March 11, 2016 0

The Diagnosed Dead Is Far from Dying Xoma (XOMA): Stock rallied following report announcing an upfront …

Jazz Pharmaceuticals: The Expected Good News on March 31, 2016

March 10, 2016 0

Of the Upcoming Game-Changing Actions THE EXPECTED FDA APPROVAL OF JAZZ DRUG DEFIBROTIDE On March 31, the FDA …

Illumina: A Great Transformation and Transition

March 8, 2016 0

As we kept describing it, Illumina’s (ILMN) is the engine behind the biological revolution reflected in the current …

Prohost Letter #393

March 4, 2016 0

Prohost Letter #393 IMMUNOTHERAPY - PROHOST PORTFOLIO - NEW PICKS? - A Brief Reminder of the CAR T –TCR …

Immune Design: Encouraging News About Treating Allergic Diseases

March 4, 2016 0

Preparing a Prohost Letter dedicated to immunotherapy and the firms that are behind the promising novel …

One Year Accomplishments Vs. One Cent Missed in Agenus Financial Report

March 3, 2016 0

Agenus (AGEN) is a project in the making since the firm has decided to play an integral …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

The Outcome of the Pfizer/Allergan Marriage. See Also: More News for Incyte

Expected and Unexpected Reasons for Pfizer and Intercept Stocks’ Rallies

Prohost Letter #394 Part 2

Gilead’s Well Chosen New Acquisition Is Not the Last, It Is Just the Beginning

Prohost Letter #394 Part 1

News from Incyte and Gossip About Medivation

The FDA Says Yes to Acadia Drug Nuplazid and More

Alder Biopharmaceutical Migraine Headache Drug Passes the Test. Our Voting Regarding Acadia Drug Nuplazid Approval

Portola Is Still a Favorite

Amgen: Positive Data from Osteoporosis Trial. Aerie Pharmaceuticals: More Data on Glaucoma Drug Safety.

Vitae Pharmaceuticals: Opening a New Door Towards the Management of Psoriasis. The Drug Could Be Great for Many Other Autoimmune Diseases.

Immunokinases Attract Roche to Blueprint Medicine. Spectrum Granted FDA Approval.

Celator: Improving on AML Standard of Care Treatment. The Stock Rallied.

GW Pharmaceuticals: A Cannabinoid Product Succeeds in Treating a Resistant Epilepsy. Stock Price Doubled.

Xoma: The Considered Dead is Alive and Kicking. Gilead is Way Undervalued

Jazz Pharmaceuticals: The Expected Good News on March 31, 2016

Illumina: A Great Transformation and Transition

Prohost Letter #393

Immune Design: Encouraging News About Treating Allergic Diseases

One Year Accomplishments Vs. One Cent Missed in Agenus Financial Report